Humacyte, Inc. announced the termination of a Revenue Interest Purchase Agreement and an Option Agreement with TPC Investments, effective December 15, 2025. The company will pay $38 million and issue 5,725,190 shares of stock as part of this settlement, with the payment anticipated to be funded by a new credit facility.